Sanz Álvarez, M., Martín-Aparicio, E., Luque, M., Zazo, S., Martínez-Useros, J., Eroles, P., . . . Rojo, F. (2021). The novel oral mTORC1/2 inhibitor TAK-228 reverses trastuzumab resistance in HER2-positive breast cancer models.
Citación estilo ChicagoSanz Álvarez, Marta, et al. The Novel Oral MTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-positive Breast Cancer Models. 2021.
Cita MLASanz Álvarez, Marta, et al. The Novel Oral MTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-positive Breast Cancer Models. 2021.
Precaución: Estas citas no son 100% exactas.